Immune cell–camouflaged surface-engineered nanotherapeutics for cancer management. (1st January 2023)

• Record Type: Journal Article
• Authors: Jain, Naitik; Shahrukh, Syed; Famta, Paras; Shah, Saurabh; Vambhurkar, Ganesh; Khatri, Dharmendra Kumar; Singh, Shashi Bala; Srivastava, Saurabh
• Is Part Of: Acta biomaterialia. Volume 155(2023)
• Page Start: 57
• Page End: 79
• Publication Date: 2023-01-01
• Subjects: Tumor targeting -- Biomimetic -- Immune cells -- Drug delivery -- Cytokines; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1016/j.actbio.2022.11.001
• Languages: English
• ISSNs: 1742-7061

Abstract

Abstract: Nanocarriers (NCs) have shown potential in delivering hydrophobic cytotoxic drugs and tumor-specific targeting. However, the inability to penetrate the tumor microenvironment and entrapment by macrophages has limited their clinical translation. Various cell-based drug delivery systems have been explored for their ability to improve circulation half-life and tumor accumulation capabilities. Tumors are characterized by high inflammation, which aids in tumor progression and metastasis. Immune cells show natural tumor tropism and penetration inside the tumor microenvironment (TME) and are a topic of great interest in cancer drug delivery. However, the TME is immunosuppressive and can polarize immune cells to pro-tumor. Thus, the use of immune cell membrane-coated NCs has gained popularity. Such carriers display immune cell-specific surface receptors for tumor-specific accumulation but lack cell machinery. The lack of immune cell machinery makes them unaffected by the immunosuppressive TME, meanwhile maintaining the inherent tumor tropism. In this review, we discuss the molecular mechanism behind the movement of various immune cells toward TME, the preparation and characterization of membrane-coated NCs, and the efficacy of immune cell-mimicking NCs in tumor therapy. Regulatory guidelines and the bottlenecks in clinical translation are also highlighted. Statement of significance: Nanocarriers have been explored for the site-specific delivery of chemotherapeutics. However, low systemic circulation half-life, extensive entrapment by macrophages, and poor accumulation inside the tumor microenvironment prevent the clinical translation of conventional nanotherapeutics. Immune cells possess the natural tropism towards the tumor along the chemokine gradient. Hence, coating the nanocarriers with immune cell-derived membranes can improve the accumulation of nanocarriers inside the tumor. Moreover, coating with membranes derived autologous immune cells will prevent engulfment by the macrophages. Graphical abstract: Image, graphical abstract